Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$334.30 USD

334.30
2,380,998

-1.31 (-0.39%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $336.00 +1.70 (0.51%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Amgen (AMGN) Stock Moves -0.39%: What You Should Know

by Zacks Equity Research

Amgen (AMGN) closed at $334.30 in the latest trading session, marking a -0.39% move from the prior day.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

by Zacks Equity Research

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

Sweta Killa headshot

What Lies in Store for Healthcare ETFs in Q2 Earnings?

by Sweta Killa

The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?

by Zacks Equity Research

On Incyte's (INCY) second-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its lead drug, Jakafi, which has been facing stiff competition.

What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?

by Zacks Equity Research

Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.

Geron (GERN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

by Zacks Equity Research

On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Amgen (AMGN) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

Amgen (AMGN) concluded the recent trading session at $331.29, signifying a +0.1% move from its prior day's close.

The Zacks Analyst Blog NVIDIA, Meta and Amgen Galaxy Gaming

by Zacks Equity Research

NVIDIA, Meta and Amgen Galaxy Gaming are included in this Analyst Blog.

Amgen (AMGN) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Amgen (AMGN) stood at $330.97, denoting a -1.4% change from the preceding trading day.

Sheraz Mian headshot

Q2 Earnings Season Scorecard, Economic Outlook and Analyst Reports for NVIDIA, Meta & Others

by Sheraz Mian

Today's Research Daily features the Q2 earnings season scorecard and fresh research reports on NVIDIA (NVDA), Meta (META), Amgen and others.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Amgen (AMGN) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Amgen (AMGN) reachead $330.83 at the closing of the latest trading day, reflecting a +1.77% change compared to its last close.

Pfizer (PFE) Moves Forward With Once-Daily Obesity Pill Study

by Zacks Equity Research

Pfizer (PFE) is set to move forward with the development of a once-daily formulation of danuglipron, its GLP-1 candidate for obesity.

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Ahan Chakraborty headshot

Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?

by Ahan Chakraborty

Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.

Kinjel Shah headshot

AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?

by Kinjel Shah

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.

Study Shows Lilly's (LLY) Obesity Drug More Effective Than NVO's

by Zacks Equity Research

Data from a new study, also published on the JAMA website, shows that patients taking Lilly's (LLY) obesity drug are likely to lose more weight than those taking Novo's drug.

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) reachead $311.46 at the closing of the latest trading day, reflecting a +0.19% change compared to its last close.